Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and ...
Neuroinflammation represents a hallmark of many degenerative diseases, such as Alzheimer’s Disease, Parkinson’s Disease, amyotrophic lateral sclerosis, multiple sclerosis, multiple system atrophy and ...
A tiny fish is helping clinicians avoid unnecessary multi-million-dollar treatment for babies suspected of having spinal muscular atrophy ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...
After witnessing my father’s tortuous battle with the illness I wanted to understand my own risk, so I visited a brain expert ...
Detailed price information for Alterity Therapeutics Limited (PRNAF) from The Globe and Mail including charting and trades.
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding ...
ABLi Therapeutics ("ABLi"), a biotechnology company developing therapeutics to address diseases that are associated with activation of Abelson Tyrosine Kinases (c-Abl kinases), announces it has ...
Research studying the effects of cannabis on the brain has often focused on adolescents, but a new study from CU Anschutz ...
FDA fast-tracks novel Parkinson’s cell therapy NouvNeu001, advancing treatment for dopaminergic neuron loss and motor ...
Despite falling short in its recent bid to snatch Avadel from Alkermes, Lundbeck is signaling to investors that it’s not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results